AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type of Arthritis

benzinga.com/general/biotech/25/04/45079377/abbvie-scores-fda-approval-for-its-blockbuster-drug-rinvoq-to-treat-type-of-arthritis

The U.S. Food and Drug Administration on Tuesday approved AbbVie Inc.’s (NYSE:ABBV) Rinvoq (upadacitinib), 15 mg, once daily, for giant cell arteritis (GCA).
GCA is an inflammation of blood vessels, called arteries, in and around the scalp.
Earlier in April, the European Commission…

This story appeared on benzinga.com, 2025-04-29 18:34:10.
The Entire Business World on a Single Page. Free to Use →